

9 November 2022

Breast Cancer

Q1. How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies?

- **Abemaciclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : <5**
- **Abemaciclib + Fulvestrant : <5**
- **Alpelisib + Fulvestrant : 0**
- **Anthracycline (e.g. doxorubicin or epirubicin) as a single agent : 0**
- **Atezolizumab +Nab-paclitaxel/Paclitaxel : 0**
- **Capecitabine as a single agent : 22**
- **Eribulin as a single agent or in combination : <5**
- **Everolimus + Exemestane : 0**
- **Fulvestrant as a single agent : 13**
- **Lapatinib : 0**
- **Neratinib : 0**
- **Parp Inhibitors (Olaparib/Talazoparib) : <5**
- **Palbociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : 45**
- **Palbociclib + Fulvestrant : <5**
- **Pembrolizumab : 0**
- **Platinum (e.g. carboplatin or cisplatin) as a single agent : <5**
- **Ribociclib + Aromatase Inhibitor (e.g. Anastrozole, exemestane, letrozole) : 9**
- **Ribociclib + Fulvestrant : <5**
- **Sacituzumab Govitecan : <5**
- **Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent : <5**
- **Taxane and/or Anthracycline in combination : 0**
- **Trastuzumab as a single agent or in combination : 13**
- **Trastuzumab emtansine : 6**
- **Transtuzumab deruxtecan : 0**
- **Any other active systemic anti-cancer therapy**

AC Breast : <5

Cisplatin & Etoposide: <5

Denosumab : 37

Docetaxel & Cyclophosphamide: <5

D-Phesgo : 7

EC-D & Heceptin : <5

EC-D : 17

EC-D-Phesgo : 14

EC-PC : 7

9 November 2022

EC-Weekly Paclitaxel : 7
EC-Weekly Paclitaxel-Phesgo: <5
FEC 100: <5
FEC 50: <5
FEC D & Herceptin: <5
FEC D: <5
FEC D Phesgo: 7
FEC Wkly Paclitaxel Herceptin: <5
FEC Wkly Paclitaxel Phesgo
Goserelin: <5
Phesgo: 6
Vinorelbine: <5
Zoledronic Acid: 19

Q2. Does your trust participate in any clinical trials for breast cancer? If so, can you please provide the name of each trial and the number of patients taking part.

See below table.

9 November 2022

Title acronym	Full Trial Title	No of Patients Recruited
OPTIMA	OPTIMA Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis (also available in the Ulster Hospital)	29
PIONEER	PIONEER (Breast) Randomised Phase II clinical trial PIONEER- A Pre-operative window study of Letrozole plus PR agonist (Megestrol Acetate) versus Letrozole alone in post-menopausal patients with ER-positive breast cancer	34
ROSCO	Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neo-adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy	<5
SMALL	A Phase III, randomised, multi-centre trial addressing overtreatment of small, screen-detected breast cancer by comparing standard surgery with minimally invasive vacuum-assisted excision	20
NOSTRA	A prospective non-randomised multi-centre feasibility study to assess if patients with residual cancer following dual-targeted neoadjuvant chemotherapy treatment for HER2-positive, ER-negative early breast cancer can be identified by multiple ultrasound-guided tumour bed core biopsies	<5
ASTEFANIA	T-DM1 + Atezolizumab in high-risk HER2+ patients with residual disease after neoadjuvant taxane-based and HER2-targeted therapy	0 (Currently on hold)
ANTHEM	Is A Novel therapeutic mammoplasty procedure a safe and effective alternative to Mastectomy for treatment of breast cancer?	<5
RESTORE C19	Exploring the experiences and outcomes of patients not offered immediate breast reconstruction after mastectomy for breast cancer during the COVID-19 pandemic	0
POETIC A	POETIC–A : PreOperative Endocrine Therapy for Individualised Care with Abemaciclib	0 (opened 6/10/22)
IMPARTER:4	Improving Patient understanding of GEP Test Results: Phase 4	0 (opened 14/10/22)